Olema Oncology Reports First Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: May 13, 2025
SAN FRANCISCO, May 13, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2025.
Read more at globenewswire.com
